Tools
Tools
Eyre, Toby A, Kirkwood, Amy A, Gohill, Sat, Follows, George, Walewska, Renata, Walter, Harriet, Cross, Matthew, Forconi, Francesco, Shah, Nimish, Chasty, Richard, Hart, Alistair, Broom, Angus, Marr, Helen, Patten, Piers E M, Dann, Andy, Arumainathan, Arvind, Munir, Tal, Shankara, Paneesha, Bloor, Adrian, Johnston, Rosalynd, Orchard, Kim, Schuh, Anna H and Fox, Christopher P (2019) Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. British journal of haematology. ISSN 1365-2141. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Full text not available from this repository.Abstract
Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi-centre retrospective analysis of 105 R/R CLL patients who received venetoclax pre-National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1-15). 48% had TP53 disruption. At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3-kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior BTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR 23%) in BTKi-exposed patients, 92% (CR 38%) in Pi3Ki-exposed patients and 80% (CR 20%) in both (P = 0·59). With a median follow-up of 15·6 months, 1-year progression-free survival was 65·0% and 1-year overall survival was 75·1%. Dose reduction or temporary interruption did not result in an inferior progression-free or discontinuation-free survival. Risk of progression or death after stopping a prior BCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2·01 P = 0·05). Venetoclax is active and well tolerated in R/R CLL post ≥1 BCRi. Reason(s) for stopping BCRi influences venetoclax outcomes.
| Item Type: | Article |
|---|---|
| Additional Information: | This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs |
| Subjects: | WH Haemic and lymphatic systems. Haematology |
| Divisions: | Planned IP Care > Oncology and Clinical Haematology |
| Related URLs: | |
| Depositing User: | Jennifer Manders |
| Date Deposited: | 28 Feb 2019 11:59 |
| Last Modified: | 28 Feb 2019 11:59 |
| URI: | http://www.repository.uhblibrary.co.uk/id/eprint/1854 |
Actions (login required)
 |
View Item |
